Pulse Biosciences Hits Enrollment Target Early in Atrial…

Event summary

Pulse Biosciences completed enrollment of 164 patients in its NANOPULSE-AF study, three months ahead of schedule.
The study evaluates the nPulse Cardiac Catheter System for treating drug-resistant atrial fibrillation.
15 clinical sites participated, with Mount Sinai's Vivek Reddy serving as National Principal Investigator.
Investigators noted rapid adoption due to the system's efficient workflow and one-shot approach.

The big picture

The accelerated enrollment suggests strong physician interest in Pulse Biosciences' nsPFA technology, which could disrupt the $4 billion global atrial fibrillation treatment market. The study's success builds on growing demand for less invasive, more precise cardiac ablation solutions. The company's ability to scale this technology will depend on both clinical outcomes and its capacity to navigate regulatory hurdles.

What we're watching

Clinical Efficacy: Whether the nPulse system's non-thermal ablation approach will demonstrate superior safety and effectiveness in final study results.
Market Differentiation: How Pulse Biosciences positions its technology against existing ablation methods in the competitive atrial fibrillation treatment space.
Regulatory Pathway: The timeline for potential FDA approval and commercial launch following study completion and data presentation.